Heron Therapeutics | HRTX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
ALKERMES USD 331.33M 7M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
Eisai JPY 168.85B 17.02B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 10.85B 2.57B 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Omeros USD -33.16M 18.52M 2024-06
Pacira USD 126.64M 15.61M 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Surmodics USD 20.08M 31.62M 2025-06
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Veracyte USD 101.97M 10.69M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03